Please assess the completion status of the following clinical trial:

Trial Title: Parathyroid and Thymus Transplantation in DiGeorge #931

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Transplant Inclusion:~* Complete DiGeorge syndrome (typical or atypical) - may have DiGeorge as part of 22q11 hemizygosity, CHARGE association, or diabetic embryopathy or they may have no associated syndromes.~* Must have 1 of following:~  * Circulating CD3+ T cells \< 50/mm3; or~ * Circulating CD3+ T cells that also positive for CD45RA and CD62L must be \<50/mm3 or must be \< 5% of total T cells.~* Must be \<24 months old~* Laboratory studies must be done w/in 1 month of treatment:~  * Thyroid studies - if abnormal must be on therapy, if recommended by endocrinology:~ * PT and PTT must be \<2x upper limits of normal (ULN)~ * Absolute neutrophil count must be \>500/mm3~ * Platelet count must be \>50,000/mm3~ * AST and ALT must be \<5x ULN~ * Creatinine must be \<1.5 mg/dl~* Parents must agree to have infant stay in Durham until thymus biopsy is done 2-3 months post-treatment.~* Typical subjects must not have a rash with T cells on biopsy nor lymphadenopathy.~* Atypical subjects have rash with T cells on biopsy; may have lymphadenopathy.~* PHA proliferative responses must be tested 2x • Atypical: PHA response must be \<75,000cpm on 2 tests; test can be done while on immunosuppression.~Additional Criteria for Parathyroid Treatment Inclusion~* Hypoparathyroidism~* At least 1 parent must agree to be parathyroid donor~* Must require calcium supplementation to maintain ionized calcium \>1.0 mmol/L. Alternatively, intact PTH must be \<lower limit of normal when ionized calcium is \<1.2 mmol/L. (Intact PTH measured 2x pre-treatment.)~DiGeorge Treatment Exclusion:~* Heart surgery conducted \<4 weeks pre-treatment~* Heart surgery anticipated w/in 3 months of treatment~* Rejection by surgeon or anesthesiologist as surgical candidate~* Lack of sufficient muscle tissue to accept 0.2gms/kg treatment~* Prior attempts at immune reconstitution, such as bone marrow treatment or previous thymus treatment~* Doesn't commit to remaining at Duke until thymus allograft biopsy~Parathyroid Donor Inclusion:~* Serum calcium in normal range~* Normal parathyroid hormone function~* HLA typing must be consistent with parentage.~* Must not be on anticoagulation or can come off~* Parent chosen for donation will be the 1 sharing most HLA alleles with thymus donor~* HLA-DR matching preferred over HLA class I matching. If there no HLA matching at all, then either parent will be acceptable if meets other criteria.~* Negative for EBV; CMV; HIV-1; Syphilis; West Nile virus; Hepatitis B; Hepatitis C; pregnancy; \& evidence of head/neck infection~* Fiberoptic nasolaryngoscopy shows vocal cords functioning normally.~* Normal thyroid function~* No history of cancer~* The infant-recipient has 2 living involved parents.~Parathyroid Donor Exclusion:~* Infant recipient doesn't have 2 living involved parents~* Animal tissue/organ recipient~* EBV~* CMV~* HIV-1~* Syphilis~* West Nile virus~* Hepatitis B~* Hepatitis C~* Pregnant~* Evidence of head/neck infection~* Vocal cords not functioning normally.~* Thyroid abnormalities~* Hyperparathyroidism~* History of cancer~* Mad cow disease (positive)~* SARS(and exposure)~* Smallpox exposure~Biological Mother of DiGeorge Subjects Inclusions:~Mother must be competent to consent or assent to study participation and willing to provide blood sample. No other inclusion/exclusion.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Thymus and Parathyroid transplantation (Type: EXPERIMENTAL): Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants

Based on this trial design, predict the completion outcome and termination type (if applicable).